查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1703280

RNA 疗法临床试验市场－全球产业规模、份额、趋势、机会及预测（依治疗方式、治疗阶段、治疗领域、地区及竞争情形划分，2020 年至 2030 年）

RNA Therapy Clinical Trials Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Modality, By Phase, By Therapeutic Areas, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 184 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2024 年全球 RNA 治疗临床试验市值为 28.7 亿美元，预计到 2030 年将达到 40.1 亿美元，预测期内复合年增长率为 5.73%。

市场概览
预测期 2026-2030
2024年市场规模 28.7亿美元
2030年市场规模 40.1亿美元
2025-2030 年复合年增长率 5.73%
成长最快的领域 罕见疾病
最大的市场 北美洲

RNA疗法代表了医学研究的一个前沿领域，透过针对基因表现为治疗多种疾病提供了一种变革性的方法。利用信使 RNA (mRNA)、小干扰 RNA (siRNA) 和反义寡核苷酸 (ASO) 等核糖核酸 (RNA) 分子，基于 RNA 的疗法提供了一种精准驱动的方法来调节基因活动。这种方法在治疗目前缺乏有效治疗选择的遗传疾病、传染病、癌症和罕见疾病方面具有重大前景。

与传统药物不同，RNA 疗法在基因层面发挥作用，从而能够提供更有针对性和个人化的治疗方案。全球临床试验的激增反映了 RNA 科学的进步以及 mRNA 疫苗等基于 RNA 的产品的成功开发，这些产品重新定义了医疗保健格局。这些临床试验由学术机构、製药公司和研究组织合作开展，对于在获得监管部门批准之前评估这些创新疗法的安全性和有效性至关重要。

关键市场驱动因素

RNA技术的加速创新

主要市场挑战

交付机制的复杂性

主要市场趋势

推动个人化和精准医疗

目录

第 1 章：产品概述

第二章：研究方法

第三章：执行摘要

第四章：顾客之声

第五章：全球RNA治疗临床试验市场展望

  • 市场规模和预测
    • 按价值
  • 市场占有率和预测
    • 按方式（RNA干扰、反义疗法、信使RNA、寡核苷酸、非反义、非RNAi）
    • 依阶段（第一阶段、第二阶段、第三阶段、第四阶段）
    • 依治疗领域（罕见疾病、抗感染、抗癌、神经系统、消化/代谢、肌肉骨骼、心血管呼吸、感觉、其他）
    • 按地区（北美、欧洲、亚太、南美、中东和非洲）
    • 按公司分类（2024）
  • 产品市场图
    • 按方式
    • 按阶段
    • 按治疗领域
    • 按地区

第六章：北美RNA疗法临床试验市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 北美：国家分析
    • 美国
    • 加拿大
    • 墨西哥

第七章：欧洲RNA疗法临床试验市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 欧洲：国家分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太地区RNA治疗临床试验市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 亚太地区：国家分析
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲

第九章：南美RNA疗法临床试验市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 南美洲：国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第 10 章：中东和非洲 RNA 治疗临床试验市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • MEA：国家分析
    • 阿联酋
    • 沙乌地阿拉伯
    • 南非

第 11 章：市场动态

  • 驱动程式
  • 挑战

第 12 章：市场趋势与发展

  • 合併与收购
  • 产品开发
  • 最新动态

第 13 章：竞争格局

  • IQVIA Inc.
  • ICON Plc
  • Laboratory Corporation of America Holdings
  • Charles River Laboratories International, Inc.
  • PAREXEL International Corp.
  • Syneos Health
  • Medpace Holdings, Inc.
  • Novotech Inc.
  • PPD Inc.
  • Veristat, LLC.

第 14 章：策略建议

第15章调查会社について・免责事项

简介目录
Product Code: 17089

Global RNA Therapy Clinical Trials Market was valued at USD 2.87 billion in 2024 and is projected to reach USD 4.01 billion by 2030, expanding at a CAGR of 5.73% during the forecast period.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 2.87 Billion
Market Size 2030USD 4.01 Billion
CAGR 2025-20305.73%
Fastest Growing SegmentRare Diseases
Largest MarketNorth America

RNA therapy represents a cutting-edge domain in medical research, offering a transformative approach to treating a wide range of diseases by targeting gene expression. Leveraging ribonucleic acid (RNA) molecules such as messenger RNA (mRNA), small interfering RNA (siRNA), and antisense oligonucleotides (ASOs), RNA-based therapies provide a precision-driven method to regulate gene activity. This approach holds significant promise in addressing genetic disorders, infectious diseases, cancer, and rare conditions that currently lack effective treatment options.

Unlike conventional pharmaceuticals, RNA therapies operate at the genetic level, enabling more targeted and personalized treatment solutions. The surge in clinical trials globally reflects both advancements in RNA science and the successful development of RNA-based products, such as mRNA vaccines, which have redefined the healthcare landscape. These clinical trials, conducted through collaborations between academic institutions, pharmaceutical companies, and research organizations, are pivotal in evaluating the safety and efficacy of these innovative therapies prior to regulatory approval.

Key Market Drivers

Accelerated Innovation in RNA Technology

The market's growth is largely fueled by rapid technological advancements in RNA science, reshaping the future of medicine and therapeutic development. A critical area of progress is the refinement of RNA synthesis techniques, which now enable the creation of highly specific and efficient RNA molecules customized to target particular genes or disease pathways.

For instance, in May 2022, Moderna and the nonprofit research organization IAVI announced the initiation of Phase I clinical trials for an experimental mRNA-based HIV vaccine (mRNA-1644), with initial screenings in Rwanda and South Africa.

Further innovations in RNA modification have enhanced molecular stability, reducing degradation and improving biodistribution, which extends the therapeutic effect and reduces dosing frequency-key factors in improving patient compliance. Delivery technologies have also evolved significantly, with lipid nanoparticles and polymer-based carriers protecting RNA during systemic circulation and facilitating precise cellular uptake.

Additionally, combination RNA therapies-which integrate multiple RNA modalities or pair RNA treatments with other therapeutic strategies-are under exploration, offering synergistic potential for more comprehensive disease management.

Key Market Challenges

Complexities in Delivery Mechanisms

A major challenge within the RNA therapy clinical trials market is the effective delivery of RNA molecules to specific cells or tissues. Due to their inherent fragility, RNA molecules are susceptible to enzymatic degradation and immune system activation, limiting their therapeutic utility if not adequately protected and directed.

Moreover, RNA molecules typically exhibit short biological half-lives, requiring repeated administrations to maintain therapeutic levels. Efficient delivery systems are essential to ensure therapeutic RNA reaches the intended cellular targets while minimizing systemic exposure and off-target effects.

To overcome these barriers, researchers have developed advanced delivery platforms-most notably lipid nanoparticle formulations-that encapsulate RNA, shielding it from degradation and enhancing cellular uptake. These systems can be engineered for targeted delivery, ensuring better therapeutic outcomes and minimizing toxicity.

However, challenges remain, particularly in achieving consistent delivery across varied patient profiles and disease states, making delivery optimization a key area of ongoing research and development.

Key Market Trends

Advancing Personalized and Precision Medicine

The shift toward personalized and precision medicine is a transformative trend shaping the RNA therapy clinical trials landscape. This approach leverages individual genetic and molecular profiles to tailor therapeutic interventions, significantly improving treatment outcomes and minimizing adverse effects.

In RNA therapy, personalized medicine involves designing RNA-based therapies that target patient-specific mutations or gene expressions. This enables highly focused treatment strategies, especially for rare or complex conditions.

Precision medicine goes a step further by using genetic profiling and advanced diagnostics to predict how patients will respond to specific RNA therapies. This data-driven approach enhances treatment efficacy, optimizes resource allocation in clinical trials, and supports the development of more targeted RNA-based drug candidates.

Key Market Players

IQVIA Inc.

ICON Plc

Laboratory Corporation of America Holdings

Charles River Laboratories International, Inc.

PAREXEL International Corp.

Syneos Health

Medpace Holdings, Inc.

Novotech Inc.

PPD Inc.

Veristat, LLC.

Report Scope:

In this report, the Global RNA Therapy Clinical Trials Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

RNA Therapy Clinical Trials Market, By Modality:

RNA interference

Antisense therapy Messenger RNA

Oligonucleotide

Non-antisense

Non-RNAi

RNA Therapy Clinical Trials Market, By Phase:

Phase I

Phase II

Phase III

Phase IV

RNA Therapy Clinical Trials Market, By Therapeutic Area:

Rare Diseases

Anti-infective

Anticancer

Neurological

Alimentary/Metabolic

Musculoskeletal

Cardiovascular Respiratory

Sensory

Others

RNA Therapy Clinical Trials Market, By Region:

North America

  • United States
  • Canada
  • Mexico

Europe

  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain

Asia-Pacific

  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Singapore

South America

  • Brazil
  • Argentina
  • Colombia

Middle East & Africa

  • UAE
  • Saudi Arabia
  • South Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global RNA Therapy Clinical Trials Market.

Available Customizations:

Global RNA Therapy Clinical Trials Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Types
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global RNA Therapy Clinical Trials Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Modality (RNA interference, Antisense therapy, Messenger RNA, Oligonucleotide, non-antisense, non-RNAi)
    • 5.2.2. By Phase (Phase I, Phase II, Phase III, Phase IV)
    • 5.2.3. By Therapeutic Areas (Rare Diseases, Anti-infective, Anticancer, Neurological, Alimentary/Metabolic, Musculoskeletal, Cardiovascular Respiratory, Sensory, Others)
    • 5.2.4. By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa)
    • 5.2.5. By Company (2024)
  • 5.3. Product Market Map
    • 5.3.1. By Modality
    • 5.3.2. By Phase
    • 5.3.3. By Therapeutic Areas
    • 5.3.4. By Region

6. North America RNA Therapy Clinical Trials Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Modality
    • 6.2.2. By Phase
    • 6.2.3. By Therapeutic Areas
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States RNA Therapy Clinical Trials Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Modality
        • 6.3.1.2.2. By Phase
        • 6.3.1.2.3. By Therapeutic Areas
    • 6.3.2. Canada RNA Therapy Clinical Trials Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Modality
        • 6.3.2.2.2. By Phase
        • 6.3.2.2.3. By Therapeutic Areas
    • 6.3.3. Mexico RNA Therapy Clinical Trials Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Modality
        • 6.3.3.2.2. By Phase
        • 6.3.3.2.3. By Therapeutic Area

7. Europe RNA Therapy Clinical Trials Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Modality
    • 7.2.2. By Phase
    • 7.2.3. By Therapeutic Area
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany RNA Therapy Clinical Trials Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Modality
        • 7.3.1.2.2. By Phase
        • 7.3.1.2.3. By Therapeutic Area
    • 7.3.2. France RNA Therapy Clinical Trials Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Modality
        • 7.3.2.2.2. By Phase
        • 7.3.2.2.3. By Therapeutic Area
    • 7.3.3. United Kingdom RNA Therapy Clinical Trials Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Modality
        • 7.3.3.2.2. By Phase
        • 7.3.3.2.3. By Therapeutic Area
    • 7.3.4. Italy RNA Therapy Clinical Trials Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Modality
        • 7.3.4.2.2. By Phase
        • 7.3.4.2.3. By Therapeutic Area
    • 7.3.5. Spain RNA Therapy Clinical Trials Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Modality
        • 7.3.5.2.2. By Phase
        • 7.3.5.2.3. By Therapeutic Area

8. Asia-Pacific RNA Therapy Clinical Trials Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Modality
    • 8.2.2. By Phase
    • 8.2.3. By Therapeutic Area
    • 8.2.4. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China RNA Therapy Clinical Trials Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Modality
        • 8.3.1.2.2. By Phase
        • 8.3.1.2.3. By Therapeutic Area
    • 8.3.2. Japan RNA Therapy Clinical Trials Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Modality
        • 8.3.2.2.2. By Phase
        • 8.3.2.2.3. By Therapeutic Area
    • 8.3.3. India RNA Therapy Clinical Trials Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Modality
        • 8.3.3.2.2. By Phase
        • 8.3.3.2.3. By Therapeutic Area
    • 8.3.4. South Korea RNA Therapy Clinical Trials Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Modality
        • 8.3.4.2.2. By Phase
        • 8.3.4.2.3. By Therapeutic Area
    • 8.3.5. Australia RNA Therapy Clinical Trials Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Modality
        • 8.3.5.2.2. By Phase
        • 8.3.5.2.3. By Therapeutic Area

9. South America RNA Therapy Clinical Trials Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Modality
    • 9.2.2. By Phase
    • 9.2.3. By Therapeutic Area
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil RNA Therapy Clinical Trials Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Modality
        • 9.3.1.2.2. By Phase
        • 9.3.1.2.3. By Therapeutic Area
    • 9.3.2. Argentina RNA Therapy Clinical Trials Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Modality
        • 9.3.2.2.2. By Phase
        • 9.3.2.2.3. By Therapeutic Area
    • 9.3.3. Colombia RNA Therapy Clinical Trials Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Modality
        • 9.3.3.2.2. By Phase
        • 9.3.3.2.3. By Therapeutic Area

10. Middle East and Africa RNA Therapy Clinical Trials Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Modality
    • 10.2.2. By Phase
    • 10.2.3. By Therapeutic Area
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. UAE RNA Therapy Clinical Trials Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Modality
        • 10.3.1.2.2. By Phase
        • 10.3.1.2.3. By Therapeutic Area
    • 10.3.2. Saudi Arabia RNA Therapy Clinical Trials Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Modality
        • 10.3.2.2.2. By Phase
        • 10.3.2.2.3. By Therapeutic Area
    • 10.3.3. South Africa RNA Therapy Clinical Trials Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Modality
        • 10.3.3.2.2. By Phase
        • 10.3.3.2.3. By Therapeutic Area

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition
  • 12.2. Product Development
  • 12.3. Recent Developments

13. Competitive Landscape

  • 13.1. IQVIA Inc.
    • 13.1.1. Business Overview
    • 13.1.2. Company Snapshot
    • 13.1.3. Products & Services
    • 13.1.4. Financials (As Reported)
    • 13.1.5. Recent Developments
    • 13.1.6. Key Personnel Details
    • 13.1.7. SWOT Analysis
  • 13.2. ICON Plc
  • 13.3. Laboratory Corporation of America Holdings
  • 13.4. Charles River Laboratories International, Inc.
  • 13.5. PAREXEL International Corp.
  • 13.6. Syneos Health
  • 13.7. Medpace Holdings, Inc.
  • 13.8. Novotech Inc.
  • 13.9. PPD Inc.
  • 13.10. Veristat, LLC.

14. Strategic Recommendations

15. About Us & Disclaimer